Crenezumab

From Aaushi
Jump to navigation Jump to search

Mechanism of action

Clinical trials

Notes

  • Crenezumab was developed by the Swiss-based biopharmaceutical company AC Immune SA, which licensed the drug in 2006 to Genentech[2]

More general terms

Additional terms

References

  1. Belluck P New Drug Trial Seeks to Stop Alzheimer's Before It Starts New York Times< May 15, 2012 http://www.nytimes.com/2012/05/16/health/research/prevention-is-goal-of-alzheimers-drug-trial.html
  2. 2.0 2.1 Wikipedia: Crenezumab http://en.wikipedia.org/wiki/Crenezumab
  3. 3.0 3.1 Yang T, Dang Y, Ostaszewski B, Mengel D et al Target engagement in an alzheimer trial: Crenezumab lowers amyloid beta oligomers in cerebrospinal fluid Ann Neurol. 2019 Aug;86(2):215-224 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31168802 Free PMC article Clinical Trial.
  4. 4.0 4.1 Ostrowitzki S, Bittner T, Sink KM et al Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer DiseaseTwo Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022;79(11):1113-1121. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36121669 PMCID: PMC9486635 Free PMC article https://jamanetwork.com/journals/jamaneurology/fullarticle/2796551